Synergistic Interaction of the Class IIa HDAC Inhibitor CHDI0039 with Bortezomib in Head and Neck Cancer Cells

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Mar 29

PMID 36982651

Authors

Christian Schrenk

Lukas M Bollmann

Corinna Haist

Arthur Bister

Constanze Wiek

Maria Wecker

Dennis Roth

Patrick Petzsch

Karl Kohrer

Alexandra Hamacher

Helmut Hanenberg

Georg Fluegen

Matthias U Kassack

Affiliations

Soon will be listed here.

Abstract

In contrast to class I/IIb/pan histone deacetylase inhibitors (HDACi), the role of class IIa HDACi as anti-cancer chemosensitizing agents is less well understood. Here, we studied the effects of HDAC4 in particular and the class IIa HDACi CHDI0039 on proliferation and chemosensitivity in Cal27 and cisplatin-resistant Cal27CisR head and neck squamous cell cancer (HNSCC). HDAC4 and HDAC5 overexpression clones were generated. HDAC4 overexpression (Cal27_HDAC4) increased proliferation significantly compared to vector control cells (Cal27_VC). Chicken chorioallantoic membrane (CAM) studies confirmed the in vitro results: Cal27_HDAC4 tumors were slightly larger than tumors from Cal27_VC, and treatment with CHDI0039 resulted in a significant decrease in tumor size and weight of Cal27_HDAC4 but not Cal27_VC. Unlike class I/pan-HDACi, treatment with CHDI0039 had only a marginal impact on cisplatin cytotoxicity irrespective of HDAC4 and HDAC5 expression. In contrast, the combination of CHDI0039 with bortezomib was synergistic (Chou-Talalay) in MTT and caspase 3/7 activation experiments. RNAseq indicated that treatment with CHDI0039 alters the expression of genes whose up- or downregulation is associated with increased survival in HNSCC patients according to Kaplan-Meier data. We conclude that the combination of class IIa HDACi with proteasome inhibitors constitutes an effective treatment option for HNSCC, particularly for platinum-resistant cancers.

Citing Articles

HDAC4/5 Inhibitor, LMK-235 Improves Animal Voluntary Movement in MPTP-Induced Parkinson's Disease Model.

Lee H, Kim H, Min J, Lee E, Choi D, Choi J Pharmacol Res Perspect. 2025; 13(1):e70057.

PMID: 39806528 PMC: 11729409. DOI: 10.1002/prp2.70057.

Synthesis and biological evaluation of -phenyl phenylhydroxamic acids containing phenothiazine with improved selectivity for class IIa histone deacetylases.

Hsu K, Huang Y, Chu J, Huang Y, Hu J, Lin T J Enzyme Inhib Med Chem. 2024; 39(1):2406025.

PMID: 39316378 PMC: 11423540. DOI: 10.1080/14756366.2024.2406025.

Targeting histone deacetylases in head and neck squamous cell carcinoma: molecular mechanisms and therapeutic targets.

Xu M, Hou Y, Li N, Yu W, Chen L J Transl Med. 2024; 22(1):418.

PMID: 38702756 PMC: 11067317. DOI: 10.1186/s12967-024-05169-9.

References

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

Morel D, Jeffery D, Aspeslagh S, Almouzni G, Postel-Vinay S . Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise. Nat Rev Clin Oncol. 2019; 17(2):91-107. DOI: 10.1038/s41571-019-0267-4. View

Zeng L, Yang X, Wen Y, Mail S, Wang M, Zhang M . Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma. Aging (Albany NY). 2016; 8(6):1236-49. PMC: 4931829. DOI: 10.18632/aging.100980. View

Vasudevan A, Hoffmann M, Beck M, Poschmann G, Petzsch P, Wiek C . HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition. Int J Mol Sci. 2019; 20(9). PMC: 6539474. DOI: 10.3390/ijms20092135. View

Sinatra L, Bandolik J, Roatsch M, Sonnichsen M, Schoeder C, Hamacher A . Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual-Targeting HDAC Inhibitors and HDAC Degraders (PROTACs). Angew Chem Int Ed Engl. 2020; 59(50):22494-22499. PMC: 7756583. DOI: 10.1002/anie.202006725. View

Prieto C, Barrios D . RaNA-Seq: Interactive RNA-Seq analysis from FASTQ files to functional analysis. Bioinformatics. 2019; . DOI: 10.1093/bioinformatics/btz854. View

Chou T . Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010; 70(2):440-6. DOI: 10.1158/0008-5472.CAN-09-1947. View

Harada T, Hideshima T, Anderson K . Histone deacetylase inhibitors in multiple myeloma: from bench to bedside. Int J Hematol. 2016; 104(3):300-9. DOI: 10.1007/s12185-016-2008-0. View

Spaety M, Gries A, Badie A, Venkatasamy A, Romain B, Orvain C . HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73/BIK Pathway. Cancers (Basel). 2019; 11(11). PMC: 6896094. DOI: 10.3390/cancers11111747. View

10.

Jia J, Han Z, Wang X, Zheng X, Wang S, Cui Y . H2B gene family: A prognostic biomarker and correlates with immune infiltration in glioma. Front Oncol. 2022; 12:966817. PMC: 9641242. DOI: 10.3389/fonc.2022.966817. View

11.

Ahn M, Kang D, Na Y, Yoon S, Choi W, Kang K . Histone deacetylase inhibitor, apicidin, inhibits human ovarian cancer cell migration via class II histone deacetylase 4 silencing. Cancer Lett. 2012; 325(2):189-99. DOI: 10.1016/j.canlet.2012.06.017. View

12.

Wang X, Chen X, Tian Y, Jiang D, Song Y . Long Noncoding RNA Acts as a microRNA-574 Sponge Thereby Enhancing the Aggressiveness of Gastric Cancer via HDAC4 Upregulation. Onco Targets Ther. 2020; 13:1691-1704. PMC: 7047994. DOI: 10.2147/OTT.S234144. View

13.

Autin P, Blanquart C, Fradin D . Epigenetic Drugs for Cancer and microRNAs: A Focus on Histone Deacetylase Inhibitors. Cancers (Basel). 2019; 11(10). PMC: 6827107. DOI: 10.3390/cancers11101530. View

14.

Lee B, Kim Y, Kim H, Kim D, Won H, Kim Y . HDAC4 degradation by combined TRAIL and valproic acid treatment induces apoptotic cell death of TRAIL-resistant head and neck cancer cells. Sci Rep. 2018; 8(1):12520. PMC: 6104079. DOI: 10.1038/s41598-018-31039-8. View

15.

Hontecillas-Prieto L, Flores-Campos R, Silver A, de Alava E, Hajji N, Garcia-Dominguez D . Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials. Front Genet. 2020; 11:578011. PMC: 7516260. DOI: 10.3389/fgene.2020.578011. View

16.

Li Y, Seto E . HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harb Perspect Med. 2016; 6(10). PMC: 5046688. DOI: 10.1101/cshperspect.a026831. View

17.

Engelke L, Hamacher A, Proksch P, Kassack M . Ellagic Acid and Resveratrol Prevent the Development of Cisplatin Resistance in the Epithelial Ovarian Cancer Cell Line A2780. J Cancer. 2016; 7(4):353-63. PMC: 4749356. DOI: 10.7150/jca.13754. View

18.

Bandolik J, Hamacher A, Schrenk C, Weishaupt R, Kassack M . Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines. Int J Mol Sci. 2019; 20(12). PMC: 6627993. DOI: 10.3390/ijms20123052. View

19.

Wu X, Dong L, Zhang R, Ying K, Shen H . Transgelin overexpression in lung adenocarcinoma is associated with tumor progression. Int J Mol Med. 2014; 34(2):585-91. DOI: 10.3892/ijmm.2014.1805. View

20.

Asfaha Y, Schrenk C, Avelar L, Lange F, Wang C, Bandolik J . Novel alkoxyamide-based histone deacetylase inhibitors reverse cisplatin resistance in chemoresistant cancer cells. Bioorg Med Chem. 2019; 28(1):115108. DOI: 10.1016/j.bmc.2019.115108. View